טוען...
Regulation of innate and adaptive antitumor immunity by IAP antagonists
Inhibition of the T-cell co-inhibitory checkpoint receptors or their ligands CTLA-4, PD-1 and PD-L1 using monoclonal antibodies has proven to be highly effective against many cancers. Yet many cancers remain resistant to checkpoint blockade, and durable remissions occur in only a minority of patient...
שמור ב:
| הוצא לאור ב: | Immunotherapy |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Future Medicine Ltd
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6462841/ https://ncbi.nlm.nih.gov/pubmed/29807457 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/imt-2017-0185 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|